New: Introducing the Finviz Crypto Map

Learn More
Last Close
Jul 18 03:59PM ET
0.8400
Dollar change
-0.3300
Percentage change
-28.21
%
Index- P/E- EPS (ttm)-1.98 Insider Own22.32% Shs Outstand7.91M Perf Week-30.00%
Market Cap8.26M Forward P/E- EPS next Y-0.93 Insider Trans0.00% Shs Float7.64M Perf Month-29.41%
Enterprise Value8.39M PEG- EPS next Q-0.37 Inst Own10.40% Short Float7.91% Perf Quarter5.66%
Income-11.09M P/S- EPS this Y30.74% Inst Trans0.32% Short Ratio0.43 Perf Half Y-59.02%
Sales0.00M P/B- EPS next Y41.88% ROA-320.45% Short Interest0.60M Perf YTD-63.00%
Book/sh-0.94 P/C5.04 EPS next 5Y29.48% ROE- 52W High6.00 -86.00% Perf Year-86.14%
Cash/sh0.17 P/FCF- EPS past 3/5Y38.88% 32.00% ROIC- 52W Low0.72 16.13% Perf 3Y-97.87%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility17.27% 9.89% Perf 5Y-99.58%
Dividend TTM- EV/Sales- EPS Y/Y TTM59.38% Oper. Margin- ATR (14)0.13 Perf 10Y-98.40%
Dividend Ex-Date- Quick Ratio0.21 Sales Y/Y TTM- Profit Margin- RSI (14)29.13 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.21 EPS Q/Q42.69% SMA20-27.74% Beta0.14 Target Price6.00
Payout- Debt/Eq- Sales Q/Q- SMA50-28.29% Rel Volume0.59 Prev Close1.17
Employees27 LT Debt/Eq- EarningsMay 15 AMC SMA200-46.21% Avg Volume1.40M Price0.84
IPOMay 28, 2003 Option/ShortNo / Yes EPS/Sales Surpr.53.61% - Trades Volume819,677 Change-28.21%
Date Action Analyst Rating Change Price Target Change
Feb-04-21Upgrade Maxim Group Hold → Buy $12
Nov-17-20Downgrade Maxim Group Buy → Hold
Dec-19-16Reiterated Maxim Group Buy $5 → $6
Dec-22-15Reiterated Maxim Group Buy $14 → $5
Jul-17-25 04:30PM
Jul-08-25 07:00AM
Jun-16-25 08:30AM
May-28-25 05:36AM
May-27-25 07:00AM
07:24AM Loading…
May-20-25 07:24AM
03:03AM
May-19-25 10:32PM
07:00AM
May-15-25 04:05PM
07:30AM
May-07-25 06:30AM
May-06-25 07:00AM
Apr-29-25 06:30AM
Apr-10-25 07:30AM
03:01AM Loading…
Apr-01-25 03:01AM
Mar-31-25 11:41PM
10:48AM
07:00AM
Mar-26-25 08:15AM
Mar-24-25 07:00AM
Dec-30-24 08:00AM
Dec-09-24 07:00AM
Dec-03-24 07:00AM
Dec-02-24 07:00AM
Nov-14-24 04:30PM
Nov-11-24 06:00AM
Oct-30-24 06:00AM
Oct-28-24 06:00AM
Oct-07-24 07:00AM
06:00AM Loading…
Sep-24-24 06:00AM
Sep-16-24 12:07PM
Aug-14-24 07:05AM
Aug-07-24 06:00AM
Jul-24-24 08:30AM
Jul-01-24 06:00AM
Jun-27-24 09:15AM
Jun-26-24 08:00AM
Jun-20-24 06:00AM
Jun-14-24 12:01PM
May-20-24 06:00AM
May-14-24 10:53PM
04:30PM
May-01-24 07:31AM
Apr-16-24 06:30PM
Apr-11-24 06:00AM
Apr-10-24 06:00AM
Apr-09-24 06:00AM
Apr-08-24 06:00AM
Apr-01-24 08:05AM
Feb-27-24 06:30AM
Feb-23-24 06:00AM
Feb-13-24 06:30AM
Dec-27-23 09:30AM
Dec-26-23 07:30AM
Dec-20-23 09:00AM
Dec-07-23 08:40AM
Nov-20-23 08:10AM
Nov-17-23 07:00AM
Nov-15-23 01:53PM
03:29AM
Nov-14-23 07:05AM
Nov-08-23 08:00AM
Nov-07-23 06:00AM
Oct-24-23 07:00AM
Oct-23-23 10:05AM
Oct-18-23 08:01AM
06:00AM
Oct-02-23 07:00AM
Sep-27-23 10:48PM
06:15PM
07:00AM
Sep-26-23 12:17PM
Sep-25-23 08:13AM
Aug-18-23 08:34AM
Aug-15-23 03:11AM
Aug-14-23 07:05AM
Aug-07-23 04:05PM
Jul-17-23 09:15AM
Jul-12-23 07:00AM
Jul-07-23 07:00AM
Jun-20-23 09:06AM
Jun-16-23 07:00AM
Jun-06-23 06:00AM
May-23-23 11:35AM
May-19-23 07:30AM
May-18-23 08:55AM
May-17-23 02:41PM
May-15-23 07:05AM
May-09-23 06:00AM
Apr-24-23 07:00AM
Apr-07-23 07:30AM
Apr-05-23 07:46PM
Apr-04-23 09:12AM
Mar-30-23 07:05AM
Mar-27-23 09:15AM
06:00AM
Mar-21-23 08:18AM
Jan-10-23 07:00AM
Jan-05-23 07:30AM
Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lebovits ChaimPresident & CEOOct 01 '24Buy3.431,8366,29280,960Oct 02 08:00 AM
Lebovits ChaimPresident & CEOSep 30 '24Buy0.2322,0005,0161,186,865Oct 02 08:00 AM